# OpenAI acquisition of Orchestra Bio

OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and is combining its team and technology with Rosalind, OpenAI's AI models and tools for life sciences research. A new medicine takes roughly 10 to 15 years on average from target discovery to US regulatory approval, and teams must orchestrate programs across internal departments and external partners, often relying on disconnected systems. The stated aim is to build agents that connect scientific findings with the studies, decisions and next steps needed to advance a potential medicine.

OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and is combining its team and technology with Rosalind, OpenAI's AI models and tools for life sciences research. A new medicine takes roughly 10 to 15 years on average from target discovery to US regulatory approval, and teams must orchestrate programs across internal departments and external partners, often relying on disconnected systems. The stated aim is to build agents that connect scientific findings with the studies, decisions and next steps needed to advance a potential medicine.